

Bharat Serums and Vaccines takes initiative to ensure compliance in assisted reproduction methods

25 July 2023 | News

Enabling ART centres/clinics to implement the requirements of the Assisted Reproductive Technology Regulations, 2021 for greater compliance



Mumbai-based biopharmaceutical firm Bharat Serums and Vaccines has roped in Bureau Veritas (India) Pvt. Ltd. (BVIL), a world leader in Audit and Certification Services - as part of the BSV ART Act Readiness Programme.

This programme aims to assess 50+ IVF centres/clinics (in the first six months) and help them implement the requirements of the Assisted Reproductive Technology Regulations, 2021 (the ART Act), driving them towards greater compliance.

Through an intensive survey, BVIL, will assess and then certify these centres with a Platinum, Gold and Silver rating depending on their level of readiness, ahead of the final inspection by the State authorities.

In accordance with the BSV ART Act, IVF centres/clinics need to be inspected by State Boards to be registered as Level 1 / Level 2 Clinics & Surrogacy Clinics. 'The ART Act Readiness Assessment Programme of BSV' assesses the current state of these centres against six critical parameters: infrastructure; people and competency management; communication; patient and process selection; data records and compliance monitoring and identifies the gaps/areas of improvement that the centres need to address to become a model-code as described in the Act.

Speaking on this Vishwanath Swarup, COO- Domestic Operations, BSV, said "The Assisted Reproductive Technology Regulations (ART), 2021 aims at the regulation and supervision of ART clinics and banks, to prevent misuse and ensure adherence to safe and ethical practice of ART services. On the occasion of World IVF Day (July 25), as responsible leaders in IVF treatment, we are delighted to announce a first-of-its-kind initiative from BSV - 'The ART Act Readiness Assessment Programme'.